These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 8913338)

  • 1. Isolation and characterization of a cisplatin-resistant strain of Schizosaccharomyces pombe.
    Perego P; Jimenez G; Howell SB
    Mol Pharmacol; 1996 Nov; 50(5):1080-6. PubMed ID: 8913338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
    Andrews PA; Velury S; Mann SC; Howell SB
    Cancer Res; 1988 Jan; 48(1):68-73. PubMed ID: 3335000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance.
    Zinkewich-Péotti K; Andrews PA
    Cancer Res; 1992 Apr; 52(7):1902-6. PubMed ID: 1551119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single step selection of cis-diamminedichloroplatinum(II) resistant mutants from a human ovarian carcinoma cell line.
    McLaughlin K; Stephens I; McMahon N; Brown R
    Cancer Res; 1991 Apr; 51(8):2242-5. PubMed ID: 1901242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line.
    Naredi P; Heath DD; Enns RE; Howell SB
    Cancer Res; 1994 Dec; 54(24):6464-8. PubMed ID: 7987844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells.
    Richon VM; Schulte N; Eastman A
    Cancer Res; 1987 Apr; 47(8):2056-61. PubMed ID: 3828995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of determinants of cadmium sensitivity in the tolerance of Schizosaccharomyces pombe to cisplatin.
    Perego P; Vande Weghe J; Ow DW; Howell SB
    Mol Pharmacol; 1997 Jan; 51(1):12-8. PubMed ID: 9016341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells.
    Waud WR
    Cancer Res; 1987 Dec; 47(24 Pt 1):6549-55. PubMed ID: 3677093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug.
    Wallner KE; DeGregorio MW; Li GC
    Cancer Res; 1986 Dec; 46(12 Pt 1):6242-5. PubMed ID: 3779644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulation of cis-diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: an altered response in accumulation-defective resistant cells.
    Marverti G; Andrews PA
    Clin Cancer Res; 1996 Jun; 2(6):991-9. PubMed ID: 9816260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
    Samimi G; Howell SB
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Establishment of a human nasopharyngeal carcinoma drug-resistant cell line CNE2/DDP and screening of drug-resistant genes].
    Jiang RD; Zhang LX; Yue W; Zhu YF; Lu HJ; Liu X; Cen XT; Guan XY; Li CH
    Ai Zheng; 2003 Apr; 22(4):337-45. PubMed ID: 12703984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of heterothallic haploid and auxotrophic mutants of Schizosaccharomyces japonicus.
    Furuya K; Niki H
    Yeast; 2009 Apr; 26(4):221-33. PubMed ID: 19330769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Establishment of human ovarian cancer cisplatin resistant cell line COC1/DDP and its mechanism of resistance].
    Zhou Y; Chen H; Yang Q
    Zhonghua Yi Xue Za Zhi; 1996 Sep; 76(9):680-3. PubMed ID: 9275551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin.
    Okuda T; Lin X; Trang J; Howell SB
    Mol Pharmacol; 2005 Jun; 67(6):1852-60. PubMed ID: 15758147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extrachromosomal inheritance in Schizosaccharomyces pombe. I. Evidence for an extrakaryotically inherited mutation conferring resistance to antimycin.
    Wolf K; Burger G; Lang B; Kaudewitz F
    Mol Gen Genet; 1976 Feb; 144(1):67-73. PubMed ID: 1264063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
    Righetti SC; Perego P; Corna E; Pierotti MA; Zunino F
    Cell Growth Differ; 1999 Jul; 10(7):473-8. PubMed ID: 10437915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
    Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
    Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.